Select Page

BURLINGAME, Calif., Oct. 06, 2020 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the formation of the Company’s Scientific Advisory Board (“SAB”) with three leading oncology experts. The SAB will provide valuable strategic and scientific counsel to ALX Oncology’s clinical programs related to its lead product candidate, ALX148.